Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 5Mucositis 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Febrile Neutropenia 2Cytokine Release Syndrome 2Burkitt Lymphoma 2Unspecified Adult Solid Tumor, Protocol Specific 1Smoldering Multiple Myeloma 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Inflammation 1Hematologic Neoplasms 1Early Stage Triple Negative ER Low Breast Cancer 1Disease Progression 1Cryopyrin-Associated Periodic Syndromes 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Arthritis, Rheumatoid 1

Interventions

Lenalidomide 17Dexamethasone 15Calcium Dobesilate 8daratumumab 5dexamethasone acetate 4dexamethasone 21-phosphate 4carfilzomib 4auricularum 4Melphalan 4Leflunomide 3Curcumin 3isatuximab 2iberdomide 2elotuzumab 2Peripheral Blood Stem Cell Transplantation 2PVX-410 vaccine 2Denosumab 2Cyclophosphamide 2Bortezomib 2siltuximab 1selinexor 1sargramostim 1pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × Interleukin 1 Receptor Antagonist Protein × Clear all
NCT02492750 2020-03-25

Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma

Mayo Clinic

Phase 1 Completed
14 enrolled 12 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡